Fear of Cancer Recurrence: Strategies for Adaptive Coping Shelley A. Johns , PsyD, HSPP, ABPP Board Certified Clinical Health Psychologist Assistant Professor, IU School of Medicine Research Scientist, Regenstrief Institute Affiliate Faculty, Fairbanks Center for Medical Ethics Associate Member, Cancer Prevention/Control, IUSCC
Agenda • Defining fear of cancer recurrence (FCR) • Significance of the problem • Assessing YOUR fear • Strategies for adaptive coping • Mindfulness • Values-based action
Fear of Cancer Recurrence (FCR) Lebel et al, 2016 “Fear , worry, or concern about cancer returning or progressing .”
Significance • Prevalence – Mild/transient FCR is almost universal. – 40-70% of survivors report clinically significant FCR (Thewes et al., 2012; NCCN Survivorship Guidelines, 2015). • Trajectory – FCR remains stable over the survivorship trajectory, even when risk of recurrence is low (Simard et al., 2013). • Unmet need – FCR is the most frequently endorsed unmet supportive care need among survivors (Armes et al., 2009; Harrison et al., 2011; Hodgkinson et al., 2007).
Higher FCR Is Associated With… – Younger age – Children still at home – Number/severity of symptoms – Medical comorbidities – Lower quality of life – Higher perceived risk of recurrence – Need for more support – Positive health behavior – More healthcare visits change (e.g., healthier diet, sunscreen use, avoiding tobacco, continuation of treatment)
Health Service Usage Among Survivors • High FCR is associated with excessive threat monitoring: – Hyper-vigilant self-examination – Requests for unnecessary scans – Greater number of unscheduled outpatient medical visits – Greater number of ER/ED visits – Greater use of counseling, support groups, and CAM interventions – Higher health care costs • High FCR is also associated with avoidant coping: • Of cancer screening, regular check-ups, and other medical tests • May compromise health outcomes. Thewes et al., 2012; Lebel et al., 2013
Experiential Exercise #1 Assessing YOUR Fear with FCR-7
FCR-7 Scoring • Add scores for each of the 7 questions. Not at all A little Sometimes A lot All the time 1 2 3 4 5 □ □ □ □ □ 1. I am afraid that my cancer may recur. • Total scores ≥ 17 = “clinically significant” fear. • Total scores ≥ 27 = “severe” fear. Support is available!
Adaptive Coping Strategies
Experiential Exercise #2
Experiential Exercise #3
Experiential Exercise #4
“Experiential” Exercise #5
Protective Factors
Opportunities • Healthy IU – https://healthy.iu.edu/ – Mindfulness, resiliency, fitness, nutrition counseling, caregiver support, etc … • Eskenazi Health – Fear of Recurrence 4-week Resiliency course - next offering in June! – See flier for details – email sheljohn@iu.edu • IU Simon Cancer Center – “First Mondays” support groups – call 317-944-0301 • Cancer Support Community – http://cancersupportindy.org/ • – https://www.cancercare.org/
Experiential Exercise #6
THANK YOU To YOU for your participation. To Healthy IU for caring about cancer survivors.
Genomic Characterization of Cancer-Adjacent Breast: Evidence of field effects
Bladder Cancer Survivorship Recurrence and follow up for non muscle invasive
TRIPLE NEGATIVE BREAST CANCER: EXPERIENCES WITH LOCAL RECURRENCE Cleo
Components of anxiety What is fear? What is anxiety? Anxiety, fear, and the
Where are we going? My Beginning Cancer is different! Fear System
Surviving COVID 19: Mental health and coping strategies Contact PSP: (902)
2/29/16 Adaptive Immune Responses to Ranaviruses and Immune Evasion
Adaptive Treatment Strategies Getting SMART About Developing Individualized
Ou Our fear of of sharing the gos ospel 1. Feeling inadequate 2. Fear of
Adaptation and Coping Strategies to Extreme Climate Conditions: Case Study of
Anish Dave 1/24/11 Antidepressant Response MarkerRevolutionizing Depression
How Effective Are the Rapid-Acting Anti-Depressants? A RAAD-ical Argument for
Rapid-Acting Anti-Depressants? The search for the holy grail Torsten M.
Th The neurog ogenic a c antidepressant c com ompou ound, N NSI SI-189
Astrodepressants Antidepressants Targeting Astrocytes Dr. Jimmy Stehberg
Implementation of ISO/IDMP 11238 Substance Standard and Movement towards a
Treating Patients with Depression Using Coordinated Medication Management
Prevention of Postpartum Depression Jennifer L. Payne, M.D. Director , Womens
MENTAL HEALTH, BEREAVEMENT AND SUICIDE Using administrative data to
Weighty Issues with Psychotropic Use in Adolescents and Young Adults Sheila
Weve talked to you about 1.Medicines Waste 2.Over the counter prescribing
LATUDA Clinical Development Update LATUDA Meeting (Tokyo) January 2011